Compare DexCom, Inc. (DXCM) vs Remitly Global Inc (RELY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Remitly Global Inc — how do they compare? DexCom, Inc. trades at $89.35 (market cap $33.79B), while Remitly Global Inc trades at $23.4 (market cap $4.97B). The key difference: DexCom, Inc. is far larger — about 6.8× Remitly Global Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Remitly Global Inc nearer its low. Which is the better fit depends on your goals.
| DXCM | RELY | |
|---|---|---|
Market Cap | $33.79B | $4.97B |
Sector | Health | Technology |
52-Week High | $89.53 | $25.93 |
52-Week Low | $54.84 | $12.20 |
Enterprise Value | $33.24B | $4.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $87.65, up 3.42% today and near its 52-week high, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $4.66B in 2025, with net income reaching $836.30M and a 20.12% net margin. Recent Q2 2026 earnings beat expectations with $0.70 EPS, and the company raised full-year guidance, reflecting robust demand for its continuous glucose monitoring systems.
The outlook remains positive given consistent earnings beats, margin expansion, and analyst consensus favoring a buy rating with a $88.65 price target. Key risks include competitive pressures in medical devices and potential regulatory scrutiny, but growth drivers like G7 adoption and international expansion support upside potential for investors.
RELY trades at $23.14, down 5.24% over 24 hours, but maintains a bullish technical signal with key support at $22. The company reported strong Q2 2026 results, beating EPS estimates with $0.93 actual versus $0.12 expected, and revenue growth of 20% year-over-year. Profitability has improved significantly, with net income margin reaching 16.85% in 2026 from negative margins in prior years. Recent news highlights expansion into new financial services like the Global Card and regulatory approvals in the UAE.
The outlook is positive, driven by robust earnings growth, market share gains, and strategic initiatives beyond core remittances. Risks include competitive pressures and execution of new business lines. Analyst consensus is strongly bullish with a $31 price target, suggesting substantial upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Remitly Global Inc
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →
